Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kidney Biopsy Clear all
Completed Phase 1 Interventional

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

NCT02318771
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IV Lung Cancer, Stage IV Skin Melanoma
Interventions
Radiation Therapy (RT), MK-3475
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 18, 2026, 5:59 AM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 18, 2026, 5:59 AM EDT
Completed No phase listed Observational

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

NCT03626246
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions
Kidney disease
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 18, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

NCT04989959
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
[18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy
Drug · Procedure
Lead sponsor
Orhan Kemal Oz
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 18, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 18, 2026, 5:59 AM EDT
Not listed No phase listed Observational

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

NCT03630926
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hypertrophy, Bladder Stones, Kidney Stones
Interventions
NV-VPAC1 PCa Urine Diagnostic Test
Diagnostic Test
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 18, 2026, 5:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

NCT05896839
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

NCT02525263
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Neo-Kidney Augment
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 18, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

NCT00002611
View directory record Official record
Conditions
Kidney Cancer
Interventions
dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 15 Years
Enrollment
3,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 18, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

NCT01014754
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 18, 2026, 5:59 AM EDT
Withdrawn Phase 2 Interventional

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 18, 2026, 5:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 18, 2026, 5:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Epigenetic Regulation of Human Adipose Tissue Distribution

NCT02728635
View directory record Official record
Conditions
Obesity
Interventions
Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsies, FSIGTT/ RMR
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Terminated No phase listed Observational

Allosure in Simultaneous Pancreas Kidney Transplant

NCT04777617
View directory record Official record
Conditions
Kidney Pancreas Transplant
Interventions
DD-cfDNA
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 18, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

NCT05018416
View directory record Official record
Conditions
Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Newark, Delaware • Nampa, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

NCT01447914
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 5:59 AM EDT
Recruiting No phase listed Observational

PET/MR for Characterization of Renal Masses (RMs)

NCT06076538
View directory record Official record
Conditions
Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions
2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

NCT02836574
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT), Renal Biopsy
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 18, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

NCT00261950
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Sensipar (Cinacalcet HCl)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 18, 2026, 5:59 AM EDT
Completed No phase listed Observational

Comparison of Markers of Kidney Function

NCT01403766
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 18, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 18, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Active, not recruiting No phase listed Observational

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

NCT05319990
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions
Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 5:59 AM EDT
Withdrawn Phase 2 Interventional

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

NCT07218692
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Sturlimogene Erparepvec, Tivozanib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 5:59 AM EDT